The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
ApexOnco Front Page
Recent articles
What could be the four HengRui assets picked up by Bristol?
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
Chengdu Kanghong's KH815 enters human testing this month.
AACR approaches, along with ASCO abstract titles.
A biliary tract cancer trial hits on response rate, but survival data will be key.